Prognostic Gene Expression, Stemness and Immune Microenvironment in Pediatric Tumors

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Mar 6

PMID 33670534

Citations 12

Authors

David Stahl

Rainer Knoll

Andrew J Gentles

Christian Vokuhl

Andreas Buness

Ines Gutgemann

Affiliations

Soon will be listed here.

Abstract

Pediatric tumors frequently arise from embryonal cells, often displaying a stem cell-like ("small round blue") morphology in tissue sections. Because recently "stemness" has been associated with a poor immune response in tumors, we investigated the association of prognostic gene expression, stemness and the immune microenvironment systematically using transcriptomes of 4068 tumors occurring mostly at the pediatric and young adult age. While the prognostic landscape of gene expression (PRECOG) and infiltrating immune cell types (CIBERSORT) is similar to that of tumor entities occurring mainly in adults, the patterns are distinct for each diagnostic entity. A high stemness score (mRNAsi) correlates with clinical and morphologic subtype in Wilms tumors, neuroblastomas, synovial sarcomas, atypical teratoid rhabdoid tumors and germ cell tumors. In neuroblastomas, a high mRNAsi is associated with shortened overall survival. In Wilms tumors a high mRNAsi correlates with blastemal morphology, whereas tumors with predominant epithelial or stromal differentiation have a low mRNAsi and a high percentage of M2 type macrophages. This could be validated in Wilms tumor tissue ( = 78). Here, blastemal areas are low in M2 macrophage infiltrates, while nearby stromal differentiated areas contain abundant M2 macrophages, suggesting local microanatomic regulation of the immune response.

Citing Articles

Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.

Liu L, Zhang M, Cui N, Liu W, Di G, Wang Y PLoS One. 2024; 19(4):e0298004.

PMID: 38635528 PMC: 11025768. DOI: 10.1371/journal.pone.0298004.

Development and validation of a novel stemness-related prognostic model for neuroblastoma using integrated machine learning and bioinformatics analyses.

Xia Y, Wang C, Li X, Gao M, Hogg H, Tunthanathip T Transl Pediatr. 2024; 13(1):91-109.

PMID: 38323183 PMC: 10839279. DOI: 10.21037/tp-23-582.

Low-density lipoprotein receptor promotes crosstalk between cell stemness and tumor immune microenvironment in breast cancer: a large data-based multi-omics study.

Yuan Q, Lu X, Guo H, Sun J, Yang M, Liu Q J Transl Med. 2023; 21(1):871.

PMID: 38037058 PMC: 10691045. DOI: 10.1186/s12967-023-04699-y.

KIF11 As a Potential Pan-Cancer Immunological Biomarker Encompassing the Disease Staging, Prognoses, Tumor Microenvironment, and Therapeutic Responses.

Guo X, Zhou L, Wu Y, Li J Oxid Med Cell Longev. 2023; 2022:2764940.

PMID: 36742345 PMC: 9893523. DOI: 10.1155/2022/2764940.

Cell senescence-associated genes predict the malignant characteristics of glioblastoma.

Tan C, Wei Y, Ding X, Han C, Sun Z, Wang C Cancer Cell Int. 2022; 22(1):411.

PMID: 36527013 PMC: 9758946. DOI: 10.1186/s12935-022-02834-1.

References

Clara J, Monge C, Yang Y, Takebe N . Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2019; 17(4):204-232. DOI: 10.1038/s41571-019-0293-2. View

Maturu P, Overwijk W, Hicks J, Ekmekcioglu S, Grimm E, Huff V . Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Transl Oncol. 2014; 7(4):484-92. PMC: 4202801. DOI: 10.1016/j.tranon.2014.05.008. View

Shats I, Gatza M, Chang J, Mori S, Wang J, Rich J . Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2010; 71(5):1772-80. PMC: 3049992. DOI: 10.1158/0008-5472.CAN-10-1735. View

Budczies J, Klauschen F, Sinn B, Gyorffy B, Schmitt W, Darb-Esfahani S . Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012; 7(12):e51862. PMC: 3522617. DOI: 10.1371/journal.pone.0051862. View

Daily K, Ho Sui S, Schriml L, Dexheimer P, Salomonis N, Schroll R . Molecular, phenotypic, and sample-associated data to describe pluripotent stem cell lines and derivatives. Sci Data. 2017; 4:170030. PMC: 5369318. DOI: 10.1038/sdata.2017.30. View

Stahl D, Gentles A, Thiele R, Gutgemann I . Prognostic profiling of the immune cell microenvironment in Ewing´s Sarcoma Family of Tumors. Oncoimmunology. 2019; 8(12):e1674113. PMC: 6844324. DOI: 10.1080/2162402X.2019.1674113. View

Miranda A, Hamilton P, Zhang A, Pattnaik S, Becht E, Mezheyeuski A . Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proc Natl Acad Sci U S A. 2019; 116(18):9020-9029. PMC: 6500180. DOI: 10.1073/pnas.1818210116. View

Aoki T, Hino M, Koh K, Kyushiki M, Kishimoto H, Arakawa Y . Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers. Pediatr Blood Cancer. 2016; 63(8):1461-4. PMC: 5074238. DOI: 10.1002/pbc.26018. View

Kattner P, Strobel H, Khoshnevis N, Grunert M, Bartholomae S, Pruss M . Compare and contrast: pediatric cancer versus adult malignancies. Cancer Metastasis Rev. 2019; 38(4):673-682. DOI: 10.1007/s10555-019-09836-y. View

10.

Chen P, Hsu W, Han J, Xia Y, DePinho R . Cancer Stemness Meets Immunity: From Mechanism to Therapy. Cell Rep. 2021; 34(1):108597. PMC: 7839836. DOI: 10.1016/j.celrep.2020.108597. View

11.

Pinto N, Park J, Murphy E, Yearley J, McClanahan T, Annamalai L . Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors. Pediatr Blood Cancer. 2017; 64(11). DOI: 10.1002/pbc.26613. View

12.

Barrett T, Suzek T, Troup D, Wilhite S, Ngau W, Ledoux P . NCBI GEO: mining millions of expression profiles--database and tools. Nucleic Acids Res. 2004; 33(Database issue):D562-6. PMC: 539976. DOI: 10.1093/nar/gki022. View

13.

Smith B, Balanis N, Nanjundiah A, Sheu K, Tsai B, Zhang Q . A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. Cell Rep. 2018; 24(12):3353-3366.e5. PMC: 6382070. DOI: 10.1016/j.celrep.2018.08.062. View

14.

Maccalli C, Volonte A, Cimminiello C, Parmiani G . Immunology of cancer stem cells in solid tumours. A review. Eur J Cancer. 2013; 50(3):649-55. DOI: 10.1016/j.ejca.2013.11.014. View

15.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

16.

Petitprez F, De Reynies A, Keung E, Chen T, Sun C, Calderaro J . B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020; 577(7791):556-560. DOI: 10.1038/s41586-019-1906-8. View

17.

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

18.

Goltsev Y, Samusik N, Kennedy-Darling J, Bhate S, Hale M, Vazquez G . Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging. Cell. 2018; 174(4):968-981.e15. PMC: 6086938. DOI: 10.1016/j.cell.2018.07.010. View

19.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

20.

Gentles A, Newman A, Liu C, Bratman S, Feng W, Kim D . The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015; 21(8):938-945. PMC: 4852857. DOI: 10.1038/nm.3909. View